This review of 279 bladder cancer patients shows early evidence for a new drug. The study is small and has limitations that affect how sure we can be about the results. Researchers examined how well disitamab vedotin worked in people with HER2-negative or HER2-low tumors.
The results showed a 51 percent objective response rate across all patients. The median progression-free survival was about 5.5 months. Patients with HER2-low tumors responded better at 55 percent. Those with HER2-negative tumors had a 34 percent response rate.
There are important reasons to be careful with these findings. Safety details and serious side effects were not reported in this review. There was also not enough data to fully analyze overall survival.
This work provides the first comprehensive evidence for this drug in this setting. However, future high-quality studies are needed to confirm these results. Patients should discuss these options with their doctors before making changes to their care plans.